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Abstract
Background: Colorectal cancers displaying high-degree microsatellite instability (MSI-H) have an
improved prognosis compared to microsatellite stable (MSS) cancers. The observation of
pronounced lymphocytic infiltrates suggests that MSI-H cancers are inherently more immunogenic.
We aimed to compare the gene expression profiles of MSI-H and MSS cancers to provide evidence
for an activated immune response in the former.
Results: We analysed tissue from 133 colorectal cancer patients with full consent and Local Ethics
Committee approval. Genomic DNA was analysed for microsatellite instability in BAT-26. High-
quality RNA was used for microarray analysis on the Affymetrix® HG-U133A chip. Data was
analysed on GeneSpring software version 6.0. Confirmatory real-time RT-PCR was performed on
28 MSI-H and 26 MSS cancers. A comparison of 29 MSI-H and 104 MSS cancers identified 2070
genes that were differentially expressed between the two groups [P < 0.005]. Significantly, many
key immunomodulatory genes were up-regulated in MSI-H cancers. These included antigen
chaperone molecules (HSP-70, HSP-110, Calreticulin, gp96), pro-inflammatory cytokines
(Interleukin (IL)-18, IL-15, IL-8, IL-24, IL-7) and cytotoxic mediators (Granulysin, Granzyme A).
Quantitative RT-PCR confirmed up-regulation of HSP-70 [P = 0.016], HSP-110 [P = 0.002], IL-18
[P = 0.004], IL-8 [0.002] and Granulysin [P < 0.0001].
Conclusions:  The upregulation of a large number of genes implicated in immune response
supports the theory that MSI-H cancers are immunogenic. The novel observation of Heat Shock
Protein up-regulation in MSI-H cancer is highly significant in light of the recognised roles of these
proteins in innate and antigen-specific immunogenicity. Increased mRNA levels of pro-inflammatory
cytokines and cytotoxic mediators also indicate an activated anti-tumour immune response.
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Background
Colorectal cancer remains a leading cause of cancer death
in the Western world despite recent advances in surgery,
radiotherapy and chemotherapy [1]. Immunotherapy has
attracted attention as a novel treatment modality that may
exploit the host immune response against tumour cells.
However, definitive evidence that colorectal cancer cells
can stimulate a specific immune response has been
elusive.
Approximately 15–20% of sporadic colorectal cancers
and nearly all large bowel malignancies in the Hereditary
Non-Polyposis Colorectal Cancer (HNPCC) syndrome
are characterised by widespread microsatellite instability
[2,3]. Microsatellites are very short repetitive nucleotide
sequences, distributed throughout the human genome,
that are prone to insertion and deletion mutations during
DNA replication. These mutations are normally corrected
by the inherent proofreading capacity of DNA polymerase
and a group of genes involved in mismatch repair (MMR).
Defective mismatch repair allows the accumulation of
errors in microsatellites and this is termed microsatellite
instability (MSI). In HNPCC a germline mutation in a
mismatch repair gene is inherited and a subsequent "sec-
ond hit" leads to failure of MMR, resulting in MSI. In spo-
radic cancers epigenetic silencing by hypermethylation of
the MMR genes has been implicated. Despite these differ-
ences in their molecular genesis the two groups share
common clinicopathological features [4]. Several studies
have confirmed that patients with tumours displaying a
high degree of microsatellite instability (MSI-H) appear to
possess a survival advantage over those with cancers that
are microsatellite stable (MSS) [5-7]. This improvement in
outcome appears to be an inherent feature of the unstable
phenotype.
It has been shown that MSI-H cancers generate abnormal
peptides that can be used to excite cytotoxic T cell
responses in in vitro experiments [8,9]. These peptides
may act as Tumour specific antigens (TSA's) in vivo and
hence, excite a host immune response. In keeping with
this observation MSI-H cancer is characterised by the pres-
ence of a significant infiltrate of lymphocytes, a feature
that has been previously associated with better patient
prognosis [10]. Lymphocytes that infiltrate tumour epi-
thelium (intra-epithelial lymphocytes, IEL's) are specifi-
cally associated with improved survival and may be
involved in an immune response [11]. Immunohisto-
chemical analyses have shown that the IEL's infiltrating
MSI-H colorectal cancers are predominantly cytotoxic,
activated and release mediators of target cell death [12].
Follow-up analyses confirm improved survival in patients
with these tumours [13]. Increased apoptosis has also
been demonstrated in MSI-H cancers but the link between
increased lymphocyte infiltrate and apoptotic cell death
has not yet been proven. Some argue that these infiltrates
are secondary phenomena with no biological relevance
[14] and it has been suggested that intra-epithelial lym-
phocyte populations in MSI-H colorectal cancers simply
represent proliferation of resident lamina propria lym-
phocytes with no immunological activation or role.
The development of high-density data analysis techniques
such as microarray technology allows rapid gene expres-
sion profiling of tissue-derived RNA to give an mRNA
expression signature for the tissue under study. The gene
expression signature of a tumour microenvironment
reflects the interactions between tumour, stroma and host
response therein. We aimed to compare these signatures
between groups of MSI-H and MSS colorectal cancers to
identify genes that are differentially expressed between the
two phenotypes. Specifically, we focus on genes involved
in anti-tumour immune responses whose activity may be
modified in colorectal cancers, in order to clarify the
nature of any immune response in MSI-H colorectal
cancer.
Results
We analysed 133 colorectal tumours of which 29 (22%)
tumours were identified as MSI-H (Table 1). This is at the
upper end of accepted figures but reflects the frequency of
MSI-H in a subset of our tumour bank that yielded high-
quality RNA. The overall prevalence of MSI-H colorectal
cancer in our tumour bank is lower (16%) and consistent
with other large series. As expected the MSI-H group
showed a statistically significant association with the right
side of the colon (P < 0.0001, χ2 test). During histological
assessment each tumour was graded for lymphocytic infil-
tration on standard Haematoxylin and Eosin stained sec-
tions by a consultant pathologist (RF). Tumours with
minimal or mild infiltration were scored 1, those with
moderate infiltration scored 2 and those with pro-
nounced lymphocytic infiltrates were scored 3. As
expected the MSI-H cancer group had higher proportions
of tumours with moderate and pronounced infiltration
but this difference did not reach statistical significance (P=
0.287, χ2 test for trend).
An initial comparison of the gene expression profiles of
MSI-H versus MSS tumours, using a parametric unpaired
t-test (with Welch's correction for unequal variances) and
the Benjamini and Hochberg False Discovery Rate (multi-
ple correction method), identified 2070 genes that were
differentially expressed at a significance of p < 0.005
(Additional Table 1). This represents 9.3% of those
included on the chip and statistically less than 0.5% of
these genes would be selected by chance. 1293 genes
(62.5%) had significantly increased signal intensity in
MSI-H cancers and 777 genes (37.5%) had reduced signal
intensity.Molecular Cancer 2004, 3:21 http://www.molecular-cancer.com/content/3/1/21
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The clear differences between the two groups can be dem-
onstrated in a cluster map (Figure 1). This was generated
using 542 of the most significant genes in our list, selected
by performing a group comparison at p < 0.05 and the
more stringent Bonferoni multiple testing correction
(Additional Table 1). The expression signatures of the
MSI-H group on the right of the cluster map display
marked homogeneity, in contrast to the heterogeneous
MSS cancers. Four tumour profiles came from patients
who satisfied family history criteria for HNPCC (Amster-
dam criteria). These profiles were clustered amongst the
other MSI-H cancers but did not form a distinct group.
Analysis after exclusion of these HNPCC tumour profiles
yielded very similar gene lists (Additional Table 2). The
small number of HNPCC MSI-H profiles (<5) precluded
meaningful comparison of expression profiles with the
sporadic group.
1328 of our 2070 genes (64.2%) had a recognised func-
tion. We noted differences in several cancer-related genes
that were consistent with our existing knowledge of the
genetic profiles of MSI-H colorectal cancers (Table 2).
Notably, the mismatch repair gene hMLH1 had reduced
signal intensity in our MSI-H group, as did the TGFβ RII
and IGFIIR genes. The mismatch repair gene PMS2 was
also underexpressed in our MSI-H cancers (P = 0.003, Fold
change 1.4). The mRNA of TP53 gene was more abundant
in MSI-H tumours when compared to MSS tumours. Sim-
ilarly, the β catenin gene also had a high signal in our MSI-
H tumours. Significantly, several transcripts related to the
heat shock protein family (HSP 70, 110 and 90) were up-
regulated in MSI-H tumours (Table 2), as were several
other genes that may be involved in a putative antigen-
directed immune response. We focussed on genes relevant
to immunological responses but many other interesting
differences are evident in our list but are not discussed in
this paper.
To validate our microarray results we used real time RT-
PCR to confirm the findings on nine genes of immunolog-
ical interest. The RT-PCR results confirmed the significant
differences between the two groups (Table 1) in seven out
of the nine genes selected. The mismatch repair gene
hMLH1 was significantly down-regulated in MSI-H (Fig-
ure 2a), whilst transcription of TP53 was significantly
higher in the unstable group (Figure 2b). Similarly the
heat shock protein (HSP) 70 (Figure 2c) and HSP-110
(Figure 2d), the Interleukins (IL) 18 (Figure 2e) and IL-8
(Figure 2f), and the protease Granulysin (Figure 2g), were
all significantly up-regulated in MSI-H when compared to
the MSS group. Two analyses, IL-15 (p = 0.17) and Cas-
pase 2 (p = 0.16), had reduced sample numbers in each
Table 1: Summary of patient demographics for microarray and RT-PCR analyses.
Microsatellite Stable (MSS) Microsatellite Unstable (MSI-H)
Microarray analysis
Patients 104 27
Mean age (SD) (yrs) 69.6 (12.3) 65.5 (15.6)
Male: Female (%) 62:42 (60:40) 13:14 (48:52)
Cancers (n) 104 29
Right: Left (%) 28:76 (27:73) 19:10 (66:34)
Dukes' Stage A (%) 14 (13.5) 3 (10.3)
B (%) 48 (46.1) 15 (51.7)
C (%) 39 (37.5) 10 (34.5)
D (%) 3 (2.9) 1 (3.4)
Lymphocyte score 1(%) 78(75) 19(65.5)
2(%) 17(16.3) 6(20.7)
3(%) 9(8.7) 4(13.8)
RT-PCR analysis
Patients 26 26
Mean age (SD) (yrs) 71.4 (13.6) 66.4 (15.1)
Male: Female (%) 14:12 (54:46) 12:14 (46:54)
Cancers (n) 26 28
Right: Left (%) 17:9 (65:35) 19:9 (68:32)
Dukes' Stage A (%) 2 (7.7) 3 (10.7)
B (%) 15 (57.7) 15 (53.6)
C (%) 8 (30.8) 10 (35.7)
D (%) 1 (3.8) 0
For RT-PCR analysis groups were matched for age, tumour side and Dukes' Stage. Two MSI-H patients had two tumours each.Molecular Cancer 2004, 3:21 http://www.molecular-cancer.com/content/3/1/21
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Two-way hierarchical clustering by the 542 most significantly differentially expressed genes between MSS and MSI-H colorectal  cancers Figure 1
Two-way hierarchical clustering by the 542 most significantly differentially expressed genes between MSS and MSI-H colorectal 
cancers. Samples arranged along the x-axis and genes along the y-axis. Each square represents the expression level of a given 
gene in an individual sample. Red represents increased expression and blue represents decreased expression relative to the 
normalised expression of the gene across all samples. Samples with similar gene expression profiles are clustered together.
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group and did not reach statistical significance. However,
both showed trends of up-regulation in MSI-H cancers
consistent with the microarray analysis.
Discussion
Our study examines the differences in overall gene expres-
sion profiles in the tumour micro-environments of MSI-H
and MSS colorectal cancers. The observation that a large
number of pro-inflammatory genes are upregulated in
MSI-H colorectal cancer is a strong indicator that an
immune response is indeed activated in these tumours.
These results support the notion that the lymphocytic
infiltrates in these cancers represent immune activation
rather than simple proliferation of resident lymphocytes.
The exact nature of the immune response remains unclear
but our novel observation that heat shock proteins are
upregulated in MSI-H colorectal cancer may be highly sig-
nificant. Microarray data analysis demonstrated that sev-
eral members of the HSP family are up-regulated in MSI-
H cancers (Table 2) and RT-PCR analyses confirmed
increased levels of both HSP-110 and HSP-70 mRNA in
our MSI-H cancers. Heat shock proteins have roles in both
innate and adoptive immunity and have excited much
interest as natural adjuvants for immunotherapy [15,16].
Some members of the HSP family act directly to excite an
innate immune response that might be more marked in
MSI-H colorectal cancer. Such a response might be medi-
ated by Natural Killer cells that characteristically release
Granulysin to induce tumour cell death, a recognised fea-
ture of MSI-H colorectal cancer, which in turn releases
intra-cellular TSA's. Alternatively, the concept of "effete
malignancy", in which accumulation of mismatch errors
overwhelms the tumour cells' viability, [17] may explain
increased tumour cell death and release of TSA's. In fact,
these two possible explanations of increased apoptosis in
MSI-H colorectal cancers may actually be complementary
rather than mutually exclusive. However, the release of
TSA's into the tumour micro-environment is the pivotal
Table 2: A highly selective list of gene specific probes that are differentially expressed (P < 0.005) between MSI-H and MSS colorectal 
cancers with a fold-change of at least 1.5.
Genes Up-regulated in MSI-H Colorectal Cancer
Gene name P value Fold change
Catenin (cadherin assoc. protein) beta 1 6.5 × 10-12 2.9
Interleukin 8* 1.7 × 10-4 2.8
Granulysin* 1.3 × 10-7 2.8
Caspase 2* 6.0 × 10-8 2.4
Interleukin 24 0.004 2.3
Heat shock protein (HSP 110 family)* 2.4 × 10-5 2.2
TP53 (Li Fraumeni)* 2.5 × 10-4 2.2
Toll-like receptor 2 (TLR-2) 1.9 × 10-4 1.9
Heat shock protein 70* 3.5 × 10-6 1.8
Granzyme A 0.001 1.7
Interleukin 1β 0.004 1.7
Survivin 0.001 1.6
Calreticulin 2.9 × 10-5 1.6
Human Natural killer Cell enhancing factor 0.001 1.6
CD68 antigen 4.8 × 10-4 1.6
ICAM 1 (CD54) 0.003 1.6
Interleukin 18 (interferon-gamma inducing factor)* 0.003 1.5
Interleukin 7 4.6 × 10-4 1.5
Interleukin 15* 0.002 1.5
Genes down-regulated in MSI-H colorectal cancer
Gene name P value Fold change
Insulin-like growth factor 2 (somatomedin A) 1.9 × 10-5 4.3
TGFβ RII 9.3 × 10-5 3.0
hMLH 1* 6.7 × 10-5 2.4
P values denote results of Welch's t test with Benjamini and Hochberg False Discovery Rate. * denotes genes selected for RT-PCR analysis.Molecular Cancer 2004, 3:21 http://www.molecular-cancer.com/content/3/1/21
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Boxplots showing RT-PCR data analysis of seven genes of interest:A hMLH1, B TP53, C HSP-70, D HSP-110, E IL-18, F IL-8,  and G Granulysin Figure 2
Boxplots showing RT-PCR data analysis of seven genes of interest:A hMLH1, B TP53, C HSP-70, D HSP-110, E IL-18, F IL-8, 
and G Granulysin. Data analysed using non-parametric Mann Whitney test (P values as shown).
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step in the generation of an antigen-specific immune
response.
Heat shock proteins act as chaperone proteins in the
processing and presentation of antigenic peptides [15,16].
They promote antigen uptake and induce expression of
antigen presenting and co-stimulatory molecules on den-
dritic cells. By example, HSP-70 has been shown to recruit
dendritic cells (and T cells) and enhances their ability to
uptake antigen [18]. This is a crucial step in the cross-
priming of dendritic cells necessary for an antigen-
directed immune response [19]. The CD68 antigen,
expressed by immature dendritic cells and macrophages
that are ready to take up antigen, is included in our list of
genes up-regulated in MSI-H colorectal cancer, as is the
TLR-2 gene, one of a family of receptors to which HSP's
bind to activate dendritic cells.
Heat Shock Proteins have also been shown to induce
cytokine profiles that promote antigen-specific responses.
This role may underscore our observation that several
immunogenic interleukins are up-regulated in MSI-H can-
cers. An important function of these cytokines is to pro-
mote the presentation of antigen by dendritic cells (and
macrophages) to effector T cells. This represents another
crucial step in the development of an antigen-specific
immune response, prior to the interaction of primed cyto-
toxic (CD8+) and helper (CD4+) T cells with the tumour
cells. This interaction subsequently results in lytic tumour
cell death. Specifically, such cytokines also modulate
which arm of the T helper system is activated: Th1 activity
favours immune activity whilst Th2 pathways favour
tolerance. In this context, our data reveals significant up-
regulation of IL-18 and other pro-inflammatory cytokines
in MSI-H cancers that promote Th1 activity.
Our microarray data are validated by the existing knowl-
edge of key gene expression in MSI-H colorectal cancers.
The presence of hMLH1 mRNA was reduced in MSI-H
cancers, as shown by both microarray and RT-PCR analy-
ses. This observation reflects the fact that hMLH1 is fre-
quently silenced, due to promoter region
hypermethylation, in sporadic cancers, which formed the
majority of our MSI-H group. Other genes known to be
affected by the MSI pathway such as TGFβ RII, IGFIIR,
TP53, APC, β catenin and Bcl-2 were also differentially
expressed between our two groups [20,21]. The inclusion
of HNPCC cancers within our MSI-H group appears not to
affect the differentially expressed genes we identify and
this is likely to reflect their small number. Accrual of fur-
ther HNPCC gene expression profiles should allow us to
sub-analyse the MSI-H group in the future. However, the
immunological focus of this paper appears unaffected by
any differences in the biology of these cancers.
As expected a large number of pro-apoptotic genes were
upregulated in our MSI-H group as these cancers are char-
acterised by increased apoptosis (Table 3). The increased
levels of Bcl-2 related transcripts are consistent with previ-
ous findings despite the anti-apoptotic functions of this
gene [22,23]. Clearly, the interaction between pro-and
anti-apoptotic agents in MSI-H cancers is complex and
needs further elucidation.
Table 3: Additional genes related to apoptosis and the Major 
Histocompatibility Complex shown to be up-regulated in MSI-H 
colorectal cancer in comparison to MSS cancers.
Apoptosis related genes up-regulated in MSI-H colorectal 
cancers (P < 0.005, Benjamini and Hochberg False Discovery 
Rate)
Gene name Fold change
TNF-induced protein 1.9
Tumour necrosis factor receptor superfamily 10d 1.9
Tumour necrosis factor receptor superfamily 9 1.7
Tumour necrosis factor receptor superfamily 10b 1.7
Tumour necrosis factor receptor superfamily 6 1.6
Death-associated protein kinase 1 1.5
DNA fragmentation factor, beta polypeptide 
(caspase-activated DNase)
1.4
Bcl-2-related protein A1 2.2
Bcl-2/adenovirus E1B 19 kDa interacting protein 3-
like
1.8
Bcl-2 antagonist/killer 1.4
Bcl-2 associated athanogene 3 1.4
Bcl-2/adenovirus E1B 19 kDa interacting protein 1 1.2
Baculoviral IAP repeat-containing 3 1.6
Baculoviral IAP repeat-containing 2 1.2
Chemokine (C-X-C motif) receptor 4 1.8
CD27-binding (Siva) protein 1.5
Thioredoxin-like, 32 kDa 1.4
Mitogen-activated protein kinase kinase kinase 5 1.4
Microtubule associated protein tau 1.4
Macrophage erythroblast attacher 1.3
Testis enhanced gene transcript (BAX inhibitor 1) 1.2
Major histocompatibility complex-related genes up-
regulated in MSI-H colorectal cancer (P < 0.05, Benjamini 
and Hochberg False Discovery Rate)
Gene name Fold change
Major histocompatibility complex, class II, DR alpha 2.0
Major histocompatibility complex, class II, DQ beta 1 1.8
Major histocompatibility complex, class II, DP alpha 1 1.8
H. sapiens HLA-DMA gene 1.7
Major histocompatibility complex, class II, DR beta 1 1.6
Major histocompatibility complex, class II, DR beta 5 1.5
HLA-B associated transcript 1 1.2
Major histocompatibility complex, class I, C 1.2Molecular Cancer 2004, 3:21 http://www.molecular-cancer.com/content/3/1/21
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It is of interest that reduction of the stringency of our sta-
tistical comparison to P < 0.05 (Benjamini and Hochberg
False Discovery Rate) generates a list of 4788 differentially
expressed genes (Additional Table 1). These include sev-
eral more genes with key immunomodulatory functions.
Transcripts specific to co-stimulatory molecules (CD80
and CD86), HSP60, MHC peptides, pro-inflammatory
cytokine receptors, Perforin 1 and Caspase 9 were
amongst those that were up-regulated in MSI-H colorectal
cancers. These subsidiary data provide further evidence
that these cancers excite an antigen-specific immune
response. Closer study of HLA molecules that were up-reg-
ulated in MSI-H cancers reveals that the majority are Class
II-related (Table 3). This finding is consistent with previ-
ous studies [24,25] and supports the notion that immu-
nogenicity of these cancers relies on antigen presentation
by Antigen Presenting Cells (cross-priming) rather than
directly by the tumour. The HLA Class I molecule β2-
microglobulin has been shown to be a target for mutation
in the MSI-H pathway and this renders HLA Class I
machinery ineffective in these tumours [26]. This gene
does not, however, appear in our list of differentially
expressed genes.
This study compares gene expression profiles in 133 pri-
mary human cancers and confirms the previous finding
on a smaller sample set that microarray profiling can dif-
ferentiate cancers according to microsatellite stability sta-
tus [27]. A recent report on differential gene expression
from microarray profiling of smaller numbers of MSI-H
(n = 8) and MSS (n = 14) colorectal cancer tissue samples
yielded findings similar to ours in genes such as TP53,
IGF2, RAN, MORF4L1, ZFP36L2 and CCNF [28]. Their
observation that EIF3S2 is downregulated in MSI-H was
confirmed in our study, as was the downregulation of
TGFβ RII. However, they did not observe differences in
MMR genes, such as hMLH1 and PMS2, or indeed the
immunomodulatory genes that we report. The likely
explanation is that the smaller sample numbers used in
their analysis as well as the smaller size of their spotted
cDNA array (8000 genes) limits the sensitivity of their
microarray comparisons. Previously two groups have
reported the results of cDNA microarray comparisons of
MSI-H and MSS cancer cell lines but both were restricted
to very small numbers [29,30]. Interestingly, of the 122
differentially expressed genes identified by these two stud-
ies 33 transcripts (27%) were also included in our list of
4788 genes (P < 0.05, Benjamini and Hochberg False Dis-
covery Rate). However, some genes noted to be down-reg-
ulated in MSI-H cancer cell lines were up-regulated in the
MSI-H cancers in our analysis, and vice versa. These dis-
parities can be attributed to the fact that cancer cells cul-
tured  in vitro behave differently to cells from primary
tumours. Indeed Bertucci et al report that colorectal cancer
lines show overexpression of genes involved in cellular
proliferation and underexpression of several gene clusters,
including a cluster associated with immunomodulatory
genes, when compared to colorectal cancer tissue samples
using microarrays [28]. These biological differences and
the small numbers used in the cell line experiments
render any concordance between our data and cell line
analyses altogether encouraging.
We acknowledge that mRNA profiles cannot be presumed
to reflect functional significance at a protein level. How-
ever, the upregulation of such a large number of genes,
known to be involved in innate and antigen-specific
immune responses, in MSI-H colorectal cancer indicates a
genuine difference in host-tumour interactions. These
findings are entirely novel and add considerable weight to
the argument that MSI-H cancers excite an immune
response. Clearly, additional work on protein expression
specific to the genes we have identified will help to eluci-
date the exact nature of immune mechanisms in these
cancers.
In this study microdissection was deliberately eschewed as
our focus was the interaction between tumour, stroma
and inflammatory cells and the expression profiles there-
fore reflect contributions from each of these groups.
Microdissection would have excluded the contribution of
certain cell populations which may have important roles
in the modulation of host-tumour interactions. We have
previously extensively analysed the composition of
tumour biopsies obtained by sampling exophytic areas of
resected specimens. We consistently found that a random
sample taken from a fresh frozen segment of tumour tis-
sue contained at least 80% tumour cells (Unpublished
data). We know from experience that necrotic tumour
does not yield high quality RNA and our study included
only those samples that yielded high quality RNA and
thus, the sampling technique we used inherently excludes
necrotic tumour. It is therefore unlikely that our results are
attributable to the presence of tumour necrosis. Further-
more, a DNA microarray analysis of the gene expression
profiles of naïve versus activated tumour-specific lym-
phocytes did not show differences of gene expression in
heat shock proteins or the interleukins noted in our study
[31]. This suggests that our observations do not simply
reflect the more pronounced lymphocyte infiltrates of
MSI-H colorectal cancer although we accept that this
remains a possibility.
Conclusions
Certainly, our results provide new evidence to support the
notion that MSI-H colorectal cancers are immunogenic
and new insights into the pathways that may be involved.
Further focussed study of these cancers may clarify the
immunology of colorectal cancer and, specifically, mayMolecular Cancer 2004, 3:21 http://www.molecular-cancer.com/content/3/1/21
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provide useful targets for directing immunotherapeutic
strategies.
Methods
Patient population and microsatellite analysis
The Local Ethics Committee approved this study and all
patients gave informed consent prior to surgery. Tissue
was available from a bank of 223 colorectal cancers
resected at The Royal London Hospital between Decem-
ber 1997 and March 2003. Tissue samples of tumour and
normal mucosa were taken within 20 minutes of resection
and snap frozen in liquid nitrogen. Normal mucosa and
tumour DNA was extracted and used in PCR reactions to
amplify the mononucleotide BAT-26 marker, as described
elsewhere [32]. Products were separated and visualised on
micro-fabricated chips to identify tumours displaying
bandshifts characteristic of a high degree of microsatellite
instability [33].
Microarray profiling and analysis
Total RNA was prepared from samples using an RNeasy®
kit (QIAGEN, Hilden, Germany) and quality was assessed
on the Agilent Bioanalyser 2100. Only 129 samples, from
our tumour bank, that yielded high quality mRNA with
minimal degradation and clear 18S/28S ribosomal peaks,
were included in the analysis. Preparation of in vitro tran-
scription (IVT) products, oligonucleotide array hybridiza-
tion and scanning were performed according to
Affymetrix® (Santa Clara, California) protocols. In brief, 5
µg of total RNA from each colon tumour and T7-linked
oligo-dT primers were used for first-strand cDNA synthe-
sis. IVT reactions were performed in batches to generate
biotinylated cRNA targets, which were chemically frag-
mented at 95°C for 35 minutes. Fragmented biotinylated
cRNA (10 µg) was hybridized at 45°C for 16 hours to
Affymetrix®  high density oligonucleotide array human
HG-U133A chip, which contains 22,283 probe sets repre-
senting more than 14,500 well-substantiated human
genes. The arrays were washed and stained with streptavi-
din-phycoerythrin (SAPE, final concentration of 10 µg/
ml). Signal amplification was performed using a bioti-
nylated anti-streptavidin antibody. The array was scanned
according to the manufacturer's instructions (Affymetrix
Genechip®  Technical Manual, 2001). Scanned images
were inspected for the presence of obvious defects (arte-
facts or scratches) on the array. Defective chips were
excluded and the sample was re-analysed. To minimize
discrepancies due to variables such as sample preparation,
hybridization conditions, staining, or array lot, the raw
expression data was scaled using Affymetrix® Microarray
Suite 5.0 software. The trimmed mean signal of all probe
sets on the HG-U133A chip was adjusted to a user-speci-
fied target signal value (1500) for each array for global
scaling. No specific exclusion criteria were applied.
Comparative analysis between expression profiles for
MSI-H and MSS samples was carried out on GeneSpring™
software version 6.0 (Silicongenetics, Redwood, Califor-
nia). The "Cross gene error model for deviation from 1.0"
was active. Gene expression data was normalised in two
ways: "per chip normalisation" and "per gene normalisa-
tion". For "per chip normalisation" all expression data on
a chip is normalised to the 50th percentile of all values on
that chip. For "per gene normalisation" the data for a
given gene is normalised to the median expression level of
that gene across all samples. The data sets are then
assigned to the two groups MSI-H and MSS, and the
expression profiles of the two groups were compared
using unpaired t-tests (with Welch's correction for une-
qual variances) and multiple testing corrections to iden-
tify genes that were differentially expressed between them.
Table 4: Summary of RT-PCR details and the numbers of samples in each analysis. Analysis of hMLH1, IL-15 and Caspase2 restricted to 
smaller numbers due to limited availability of high-quality RNA.
Gene name GENBANK NUMBER Chemistry (Applied Biosystems, Warrington, UK) Sample Numbers (n)
MSS MSI-H
hMLH1 NM_000249 High-Capacity cDNA Archive Kit + TaqMan Universal PCR Master Mix 
(with AmpErase UNG)
12 16
TP53 NM_000546 TaqMan® EZ-RT-PCR Kit 26 27
HSP-70 kD 1B NM_005346 TaqMan® EZ-RT-PCR Kit 26 28
HSP-110 NM_014278 TaqMan® EZ-RT-PCR Kit 26 28
IL-18 NM_001562 TaqMan® EZ-RT-PCR Kit 24 28
IL-8 NM_000584 TaqMan® EZ-RT-PCR Kit 26 28
IL-15 NM_000585 High-Capacity cDNA Archive Kit + TaqMan Universal PCR Master Mix 
(with AmpErase UNG)
12 16
Granulysin NM_006433 TaqMan® EZ-RT-PCR Kit 26 27
Caspase 2 NM_001224 TaqMan® EZ-RT-PCR Kit 21 18Molecular Cancer 2004, 3:21 http://www.molecular-cancer.com/content/3/1/21
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RT-PCR Analysis
Nine genes were further analysed using quantitative real-
time RT-PCR. To compare similar groups each MSI-H
tumour was matched to an MSS tumour from patients of
similar age, the same side of the colon and, where possi-
ble, same Dukes' Stage. Sample RNA was extracted, quan-
tified and quality-controlled as for microarray analysis.
High-quality RNA was available on 28 tumours of the 29
tumours with MSI-H. These were matched to a group of
26 MSS cancers (Table 1). Three analyses were performed
on smaller groups (Table 4) because high-quality RNA
was no longer available for analysis. Gene-specific primers
and probe sets for each gene (Table 4) were obtained from
Assays-on-Demand Gene Expression Products (Applied
Biosystems, Warrington, UK). RT-PCR reactions were car-
ried out in a one-tube system for seven genes but reactions
for two genes were sub-optimal in this set-up and so a
two-tube system was used instead (Table 4). Sample RNA
was processed in duplicate with serial dilutions of Human
Universal Reference RNA (Stratagene, LaJolla, California),
in triplicate, and No Template Controls on the same 96-
well plate. Standard curves were constructed from the
Universal RNA wells with arbitrary units of 1 Unit equiv-
alent to 1 picogram of Universal RNA. Duplicate wells
that differed by more that one Ct count were repeated or
were excluded from the analysis. The results were com-
pared using the non-parametric Mann-Whitney test and
significance was taken at P < 0.05.
List of abbreviations
MSI = Microsatellite instability
MSI-H = High degree microsatellite instability
MSS = Microsatellite stable (including low degree
instability)
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